polyDNA

The Center for the Biology of Chronic Disease (CBCD) has learned this week that researchers have “developed a system to “see” the source of pain (inflammation)in sufferers of Fibromyalgia.

Vertex Pharmaceuticals’ new drug, “Incivek” has beaten Merck’s “Victrelis’s” sales by a gigantic margin.

According to a study by the Institute of Cancer Research, testing for the presence of the human papillomavirus (HPV) as part of cervical screening reduces the number of women who don’t really need to go in for further testing by over a third.

The Center for the Biology of Chronic Disease (CBCD) congratulates the success of Agneus, Inc.’s HerpV vaccine study.

The Center for the Biology of Chronic Disease (CBCD) believes Chronic Fatigue Syndrome may be improved and symptoms lessened by boosting the immune system against the latent Epstein Barr Virus.

Although vaccines such as Gardasil and Cervarix are now on the market to help prevent HPV transmission and cervical cancer in girls, until recently the CDC (Centers for Disease Control) was not considering recommending an HPV vaccine for young men.

The Center for the Biology of Chronic Disease (CBCD) agrees with health officials who are urging the public at large to make certain they get a flu shot this season.

Bristol-Myers Squibb Co.'s new drug called BMS-790052 in combination with peginterferon and ribavirin cured up to 83% of patients infected with Hepatitis C.

polyDNA, the makers of Gene-Eden-VIR, congratulates VBI Vaccines on its acquisition of Epixis, a biotechnology company that develops a new generation of Virus-Like Particle vaccines.

CBCD Applauds the Work of Dr. Herald zur Hausen